SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-17-040231
Filing Date
2017-06-15
Accepted
2017-06-15 17:43:29
Documents
2
Period of Report
2017-06-14

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1517
2 POA DOCUMENT poa.txt EX-24.3_731583 3276
  Complete submission text file 0001209191-17-040231.txt   6185
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET NEW YORK NY 10013
Business Address
Duncan Barbara Gayle (Reporting) CIK: 0001353128 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38085 | Film No.: 17914366

Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Issuer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations